Is the iPS marker "TRA-1-60" an indicator of cancer intractability against therapeutics?
Project/Area Number |
16K15245
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Human pathology
|
Research Institution | Niigata University |
Principal Investigator |
Kondo Eisaku 新潟大学, 医歯学系, 教授 (30252951)
|
Co-Investigator(Kenkyū-buntansha) |
奥田 修二郎 新潟大学, 医歯学系, 准教授 (00512310)
阪口 政清 岡山大学, 医歯薬学総合研究科, 准教授 (70379840)
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 膵がん / TRA-1-60 / PODXL1 / 転移 / 浸潤 / 病理学 |
Outline of Final Research Achievements |
1. PODXL1-konckout clones were generated from human three different PDAC lines since the TRA-1-60 is the glycosylated form of PODXL1. Consequently, drastic inhibition of liver metastasis in vivo was observed in all PODXL1-KO clone-xenografted mice generated from MiaPaCa-2, AsPC1, Panc-1. 2. PODXL1 revealed to form complex with multiple cytokine receptors and its binding contribute to activate those receptors. 3. PODXL1 was highly expressed at the invasive front and metastatic foci of PDAC cells in patients' tumor tissues.
|
Report
(3 results)
Research Products
(39 results)
-
-
-
-
-
-
-
[Journal Article] Association between and polymorphisms and adverse drug reactions to regorafenib: A preliminary study2017
Author(s)
Maeda A, Ando H, Ura T, Komori A, Hasegawa A, Taniguchi H, Kadowaki S, Muro K, Tajika M, Kobara M, Matsuzaki M, Hashimoto N, Maeda M, Kojima Y, Aoki M, Kondo E, Mizutani A, Fujimura A.
-
Journal Title
Int. J. Clin. Pharmacol. Ther
Volume: epub ahead of print
Issue: 05
Pages: 409-415
DOI
Related Report
Peer Reviewed
-
[Journal Article] Regulation of B cell differentiation by the ubiquitin-binding protein TAX1BP1.2016
Author(s)
Matsushita, N., Suzuki, M., Ikebe, E., Nagashima, S., Inatome, R., Asano, K., Tanaka, M., Matsushita, M., Kondo, E., Iha, H., and Yanagi, S.
-
Journal Title
Sci. Rep
Volume: 6
Issue: 1
Pages: 31266-31266
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Active Secretion of Dimerized S100A11 Induced by the Peroxisome in Mesothelioma Cells.2016
Author(s)
Saho S, Satoh H, Kondo E, Inoue Y, Yamauchi A, Murata H, Kinoshita R, Yamamoto KI, Futami J, Putranto EW, Ruma IM, Sumardika IW, Youyi C, Suzawa K, Yamamoto H, Soh J, Tomida S, Sakaguchi Y, Saito K, Iioka H, Huh NH, Toyooka S, Sakaguchi M.
-
Journal Title
Cancer Microenviron.
Volume: 9
Issue: 2-3
Pages: 93-105
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
[Journal Article] MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.2016
Author(s)
Ruma IM, Putranto EW, Kondo E, Murata H, Watanabe M, Huang P, Kinoshita R, Futami J, Inoue Y, Yamauchi A, Sumardika IW, Youyi C, Yamamoto K, Nasu Y, Nishibori M, Hibino T, Sakaguchi M.
-
Journal Title
Clin Exp Metastasis
Volume: 33
Issue: 6
Pages: 609-627
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-